Department of Respiratory Medicine, Graduate School of Medicine, Juntendo University, 3-1-3 Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.
Sci Rep. 2023 Aug 2;13(1):12528. doi: 10.1038/s41598-023-39101-w.
Nintedanib reduces the decline in forced vital capacity and extends the time to the first acute exacerbation of interstitial lung disease (AE-ILD). However, the effect of additional nintedanib administration after AE-ILD onset is unknown. This study aimed to investigate the efficacy and safety of nintedanib administration after AE-ILD development. We retrospectively collected the data of 33 patients who developed AE-ILD between April 2014 and January 2022. Eleven patients who received nintedanib after AE-ILD development and the remaining who did not were classified into the N and No-N groups, respectively. The survival time in the N group tended to be longer than that in the No-N group. The generalized Wilcoxson test revealed that the cumulative mortality at 90 days from AE-ILD onset was significantly lower in the N group. The time to subsequent AE-ILD development was significantly longer in the N group than that in the No-N group. The incidence of adverse gastrointestinal effects and liver dysfunction in the N group was 9-18%. Treatment without nintedanib after AE-ILD development and the ratio of arterial oxygen partial pressure to fractional inspired oxygen were significant independent prognostic factors in the multivariate analysis. Thus, nintedanib administration may be a treatment option for AE-ILD.
尼达尼布可减少用力肺活量的下降，并延长间质性肺病（ILD）急性加重（AE-ILD）的时间。然而，AE-ILD 发病后额外给予尼达尼布的效果尚不清楚。本研究旨在探讨 AE-ILD 发病后尼达尼布给药的疗效和安全性。我们回顾性收集了 2014 年 4 月至 2022 年 1 月间发生 AE-ILD 的 33 例患者的数据。将发病后接受尼达尼布治疗的 11 例患者和未接受治疗的其余患者分别归入 N 组和 No-N 组。N 组的生存时间似乎更长。广义 Wilcoxon 检验显示，N 组从 AE-ILD 发病起 90 天的累积死亡率显著更低。N 组发生后续 AE-ILD 的时间明显长于 No-N 组。N 组不良胃肠道反应和肝功能障碍的发生率为 9-18%。多变量分析显示，AE-ILD 发病后不给予尼达尼布治疗和动脉血氧分压与吸入氧分数比值是显著的独立预后因素。因此，尼达尼布给药可能是 AE-ILD 的一种治疗选择。
